Media stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the pharmaceutical company an impact score of 45.1129348927392 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
Shares of Vertex Pharmaceuticals (NASDAQ VRTX) traded down $0.22 during trading on Friday, hitting $160.72. The stock had a trading volume of 961,975 shares, compared to its average volume of 2,374,247. The stock has a market capitalization of $40,805.52, a price-to-earnings ratio of 154.54, a P/E/G ratio of 2.29 and a beta of 1.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.58 and a current ratio of 4.79. Vertex Pharmaceuticals has a 1 year low of $84.39 and a 1 year high of $174.96.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.53 by $0.08. The firm had revenue of $651.63 million for the quarter, compared to analyst estimates of $592.49 million. Vertex Pharmaceuticals had a return on equity of 11.02% and a net margin of 10.59%. The business’s revenue for the quarter was up 42.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.35 earnings per share. research analysts forecast that Vertex Pharmaceuticals will post 1.67 earnings per share for the current year.
Vertex Pharmaceuticals declared that its Board of Directors has approved a stock repurchase plan on Wednesday, January 31st that permits the company to buyback $500.00 million in outstanding shares. This buyback authorization permits the pharmaceutical company to reacquire shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s management believes its stock is undervalued.
Several research firms recently issued reports on VRTX. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. HC Wainwright restated a “hold” rating and issued a $103.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 13th. Deutsche Bank began coverage on Vertex Pharmaceuticals in a research note on Tuesday, December 12th. They issued a “buy” rating and a $175.00 price target for the company. Oppenheimer increased their target price on Vertex Pharmaceuticals from $175.00 to $190.00 and gave the company an “outperform” rating in a research report on Thursday, January 4th. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $205.00 target price on shares of Vertex Pharmaceuticals in a research report on Thursday, October 26th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and twenty-five have issued a buy rating to the company. Vertex Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $183.11.
In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 125,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $141.35, for a total value of $17,668,750.00. Following the completion of the sale, the chief executive officer now owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Paul M. Silva sold 9,883 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $173.50, for a total value of $1,714,700.50. Following the completion of the sale, the senior vice president now directly owns 25,228 shares of the company’s stock, valued at approximately $4,377,058. The disclosure for this sale can be found here. Insiders sold 448,320 shares of company stock worth $69,007,823 in the last quarter. 1.80% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Vertex Pharmaceuticals (VRTX) Getting Somewhat Favorable News Coverage, Report Shows” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/18/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-vertex-pharmaceuticals-vrtx-share-price.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.